 CAMBRIDGE, Mass.--BUSINESS WIRE--Scholar Rock NASDAQ: SRRK, a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced a presentation at the 2021 TGFβ for Immuno-Oncology Drug Development Summit. Inhibition of TGFβ1 Activation with SRK-181 Overcomes Primary Resistance to Checkpoint Inhibition Therapy will be presented on January 28th, 2021 at 12:30 PM EST. The presentation will provide an 